<DOC>
	<DOCNO>NCT00002510</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy radiation therapy kill cancer cell . PURPOSE : Phase I/II trial study effectiveness etoposide plus radiation therapy follow peripheral stem cell transplantation treat patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy Followed Peripheral Stem Cell Transplantation Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate overall progression-free survival patient select poor-prognosis non-Hodgkin 's lymphoma treat high-dose etoposide total-body irradiation follow rescue peripheral blood stem cell . II . Determine toxicity regimen . III . Evaluate short-term long-term engraftment characteristic patient treat regimen . OUTLINE : Patients respond Regimen A bulk disease great 5 cm treat Regimen B . Regimen A : Single-Agent Chemotherapy/Stem Cell Mobilization Urothelial Protection Growth Factor Therapy . Cyclophosphamide , CTX , NSC-26271 ; Mesna , NSC-113891 ; Granulocyte Colony Stimulating Factor ( Amgen ) , G-CSF , NSC-614629 . Regimen B : Sequential Radiotherapy , Single-Agent Chemotherapy , Stem Cell Rescue . Total-body irradiation , TBI ( equipment specify ) ; Etoposide , VP-16 , NSC-141540 ; Peripheral Blood Stem Cells , PBSC . PROJECTED ACCRUAL : 20 patient study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm nonHodgkin 's lymphomas follow histologic subtypes : Small lymphocytic Follicular small cleave cell Follicular mix cell Follicular large cell ( relapse ) Disease first , second , third partial remission ( 25 % shrinkage crosssectional area measurable disease ) first , second , subsequent relapse require Transformed nonHodgkin 's lymphoma eligible , i.e. , lowgrade lymphoma subsequently transform intermediate highgrade lymphoma No lymphosarcoma cell leukemia PATIENT CHARACTERISTICS : Age : 16 65 Performance status : Karnofsky 80100 % Hematopoietic : WBC least 5,000/mm3 ( polys least 2,000/mm3 ) Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL SGOT great 2 time normal Renal : Creatinine great 1.8 mg/dL Cardiovascular : LVEF least 50 % Pulmonary : FVC great 1.5 liter FEV1 great 1.2 liter MVV great 50 liter DLCO great 12 mL/min pO2 great 70 mm Hg room air Other : No serious psychiatric , neurologic , medical illness PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Less 3,500 cGy prior irradiation mediastinum , lung , spinal cord Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>